Pharmaceutical

Sea Pharmaceuticals Advancing Oral Neurotherapeutics as Potential Medicines for Tinnitus, Epilepsy, and ALS in Collaboration with TCG GreenChem

Sea's novel synthetic molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the central nervous system,…

1 year ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / November 14, 2024 / Lexaria…

1 year ago

NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury…

1 year ago

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding…

1 year ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

-- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a…

1 year ago

FDA authorizes the first AI-driven MRI solution for safer Alzheimer’s treatment

BOSTON and LEUVEN, Belgium, Nov. 14, 2024 /PRNewswire/ -- Why this news will impact the lives of people affected by Alzheimer's…

1 year ago

EDETEK Recognized as the highest Major Contender in Everest Group’s 2024 Clinical Data and Analytics Platforms PEAK Matrix® Assessment

PRINCETON, N.J., Nov. 13, 2024 /PRNewswire/ -- EDETEK, Inc., a leading global provider of specialized software and services for the…

1 year ago

Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024

HILLSIDE, NJ / ACCESSWIRE / November 13, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial…

1 year ago

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Net income of $1.5 millionAdjusted EBITDA1 of $1.9 millionADHD Portfolio net revenue up 1% to $15.3 millionPediatric Portfolio net revenue…

1 year ago

Inc. Names Arbor Scientia Group as a 2024 Power Partner Award Winner

Award won after analysis of pharmaceutical clients' feedback received by Inc. regarding Arbor Scientia Group's valuable strategic partnerships and tactical support …

1 year ago